|
Thomas A. Glaze, CEO
Mr. Glaze has spent over 25 years in the biotechnology industry founding and managing companies in pharmaceuticals and medical devices. Prior to joining Receptor BioLogix, he founded Essentialis, Inc., a developer of obesity drugs, and Limerick NeuroSciences, Inc., established to develop improved analgesics. Previously, he was founder and CEO for 11 years at Metabolex, Inc., a company focused on therapeutics to treat diabetes. In 1979, Mr. Glaze founded Monoclonal Antibodies, Inc., and served as its chairman and CEO until its merger with Quidel Corp. in 1991. In addition to being a board member of Receptor BioLogix, he also serves on the boards of Essentialis, Limerick, and BayBio. He is on the advisory boards of the Petit Institute for Bioengineering and Bioscience at Georgia Tech, and the Friday Harbor Labs of the University of Washington. Mr. Glaze holds an M.B.A. and an M.S. from Stanford University and a B.I.E. from the Georgia Institute of Technology.
H. Michael Shepard, Ph.D., Founder, President & CSO
Dr. Shepard brings to Receptor BioLogix an extensive background in product research and therapeutics development. While at Genentech, he led the discovery and development of the breast cancer drug, Herceptin. Formerly, he was chief scientific officer and vice president of research at Canji Inc., where he developed the application of the p53 gene product for cancer treatment. Dr. Shepard was a Damon Runyon Fellow at Indiana University and holds a bachelor's degree from UCD, and a Ph.D. from Indiana University, Bloomington.
Janet I. Swearson, Chief Financial Officer
Ms. Swearson brings to Receptor BioLogix an extensive background in successful financial management, fund raising, team building and mergers and spin-outs of early-stage life science companies. Prior to joining the company, she served as CFO, vice president, finance and operations at Threshold Pharmaceuticals, Inc., where she was instrumental in raising $151 million in public and private funds (including an IPO and a follow-on financing). Previously, she was CFO, vice president, finance and administration at Camitro Corp. until its sale to a public company. She has also served in a variety of finance and operations positions at IntraBiotics Pharmaceuticals, Inc., at Affymax participating in its IPO, sale to Glaxo Wellcome and the spin-outs of Affymetrix and Maxygen, and at Monoclonal Antibodies, Inc., until its merger with Quidel Corp. Prior to biotechnology, Ms. Swearson worked at Hewlett Packard. She received her B.A. at the University of Minnesota and her M.B.A. at Santa Clara University.
Douglas J. Kawahara, Ph.D., VP Business Development
Dr. Kawahara has more than 15 years of biotechnology industry experience, including the negotiation of in-licensing agreements, research collaborations, and pharmaceutical partnerships. Prior to joining Receptor BioLogix, he was senior director of business development at Anesiva, Inc., a biopharmaceutical company developing drugs for treating pain and inflammation. Before that, he was director of corporate development at GeneTrol Biotherapeutics, a developer of therapeutic proteins for the treatment of cancer, viral infections and autoimmune diseases. Previously, he was a member of the founding management team and corporate director of planning and business development for Xenogen Corp., and held positions of increasing responsibility at Becton Dickinson and Co. Dr. Kawahara was also director of research at Children’s Hospital Orange County, and a post-doctoral fellow at UCLA. He holds a bachelor’s degree in biology from UCSD, an M.B.A. in finance from CSU, Long Beach, and a Ph.D. in immunology from the University of Rochester.
|
|
